199 related articles for article (PubMed ID: 10705871)
1. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
Streckfus C; Bigler L; Tucci M; Thigpen JT
Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
[TBL] [Abstract][Full Text] [Related]
2. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
[TBL] [Abstract][Full Text] [Related]
3. [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].
Ruibal A; Garrido Pumar M; Arias JI
Rev Esp Med Nucl; 2006; 25(3):180-3. PubMed ID: 16762272
[TBL] [Abstract][Full Text] [Related]
4. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
[TBL] [Abstract][Full Text] [Related]
6. Salivary markers: their role in breast cancer detection.
Chase WR
J Mich Dent Assoc; 2000 Feb; 82(2):12. PubMed ID: 11323899
[No Abstract] [Full Text] [Related]
7. CA 15-3 serum levels in patients with ductal breast carcinoma: relationship with clinicopathological parameters and tumor markers.
González-Sistal A; Arias JI; Ruibal A
Int J Biol Markers; 2012; 27(1):47-52. PubMed ID: 21928245
[TBL] [Abstract][Full Text] [Related]
8. Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
[TBL] [Abstract][Full Text] [Related]
9. CA 15-3 and c-erbB-2 presence in the saliva of women.
Streckfus C; Bigler L; Dellinger T; Pfeifer M; Rose A; Thigpen JT
Clin Oral Investig; 1999 Sep; 3(3):138-43. PubMed ID: 10803125
[TBL] [Abstract][Full Text] [Related]
10. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
Wu JT; Astill ME; Gagon SD; Bryson L
J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
[TBL] [Abstract][Full Text] [Related]
11. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
12. Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men.
Streckfus C; Bigler L; Dellinger T; Dai X; Cox WJ; McArthur A; Kingman A; Thigpen JT
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Feb; 91(2):174-9. PubMed ID: 11174594
[TBL] [Abstract][Full Text] [Related]
13. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
[TBL] [Abstract][Full Text] [Related]
14. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.
Yu H; Levesque MA; Khosravi MJ; Papanastasiou-Diamandi A; Clark GM; Diamandis EP
Br J Cancer; 1996 Oct; 74(8):1242-7. PubMed ID: 8883411
[TBL] [Abstract][Full Text] [Related]
15. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67.
Shin IY; Sung NY; Lee YS; Kwon TS; Si Y; Lee YS; Oh ST; Lee IK
Gut Liver; 2014 Jan; 8(1):13-23. PubMed ID: 24516696
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status.
Sacks NP; Smith K; Norman AP; Greenall M; LeJeune S; Harris AL
Eur J Cancer; 1993; 29A(3):426-8. PubMed ID: 8398346
[TBL] [Abstract][Full Text] [Related]
17. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
20. Relation between cathepsin D expression and other prognostic factors in breast carcinomas.
Shaheen RM; Miseljic S; Wiehle RD; Wittliff JL
Clin Chem; 1995 Nov; 41(11):1585-91. PubMed ID: 7586547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
